Advicenne SA (FR:ALDVI)
:ALDVI
Want to see FR:ALDVI full AI Analyst Report?
ALDVI Stock Chart & Stats
€1.72
€0.01(0.70%)
At close: 4:00 PM EST
€1.72
€0.01(0.70%)
Day’s Range― - ―
52-Week Range€0.80 - €2.35
Previous CloseN/A
Volume979.00
Average Volume (3M)26.23K
Market Cap
€13.06M
Enterprise Value€30.02M
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume23,481
30 Day Avg. Volume26,231
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€7.20M
Bulls Say, Bears Say
Bulls Say
Specialized Niche Product And Recurring Prescription ModelAdvicenne focuses on a narrow orphan renal indication with a prescription-based chronic therapy. That specialized, recurring-revenue model supports stable per-patient lifetime value, pricing power common in rare-disease drugs, and a predictable demand profile as diagnosis and treatment penetration increase.
Commercialized Core Product (Sibnayal)Having a marketed, proprietary product establishes regulatory and commercial footholds, enabling revenue generation and payer engagement. Commercial presence reduces time-to-revenue for incremental markets and gives a platform to expand indications or geographies, supporting durable top-line growth potential.
Improving Gross Profitability In 2025A shift to positive gross margin indicates the product and cost structure now generate unit-level profit. This improvement creates room to absorb SG&A and R&D investments while moving toward sustainable profitability if volume scales and fixed costs are leveraged over time.
Bears Say
Negative Equity And Fragile Capital StructureSustained negative equity constrains financing options, can trigger covenant or counterparty concerns, and raises insolvency risk under stress. Structurally weak capital positions force reliance on dilutive equity raises or expensive funding, limiting long-term strategic flexibility.
Persistent Negative Operating And Free Cash FlowOngoing cash burn and negative FCF indicate the business cannot internally fund operations or expansion. Over months this sustains funding pressure, increases dilution or refinancing risk, and may force cutbacks in commercialization or R&D that impede durable growth.
Small, Volatile Revenues And Continued Operating LossesA small, inconsistent revenue base limits margin leverage and scale economics. Persistent operating losses mean break-even depends on sizable volume gains or margin improvements, making long-term profitability and ability to service obligations uncertain without external funding.
Advicenne SA News
ALDVI FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.80 and its highest was €2.35 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €13.06M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is in 117 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.314.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.933%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in FR:ALDVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.